Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

L0551000

Levonorgestrel

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

D(−)-Norgestrel, 13β-Ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one, 17α-Ethynyl-18-homo-19-nor-testosterone, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-yn-3-one, 18,19-Dinor-4-pregnen-20-yn-3-one, Levonorgestrel

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C21H28O2
Numero CAS:
797-63-7
Peso molecolare:
312.45
Numero MDL:
MFCD00199013
Codice UNSPSC:
41116107
ID PubChem:
329817365
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

levonorgestrel

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
WWYNJERNGUHSAO-XUDSTZEESA-N

Informazioni sul gene

human ... PGR(5241)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Levonorgestrel EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H351 - H360D - H362

Classi di pericolo

Carc. 2 - Lact. - Repr. 1A

Codice della classe di stoccaggio

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 10

1 of 10

Dienogest European Pharmacopoeia (EP) Reference Standard

Y0001785

Dienogest

Drospirenone ≥98% (HPLC)

Sigma-Aldrich

SML0147

Drospirenone

Desogestrel Related Compound C United States Pharmacopeia (USP) Reference Standard

USP

1173268

Desogestrel Related Compound C

Desogestrel impurity D British Pharmacopoeia (BP) Reference Standard

BP816

Desogestrel impurity D

D(−)-Norgestrel analytical standard

Supelco

N2260

D(−)-Norgestrel

Norethisterone European Pharmacopoeia (EP) Reference Standard

N1200000

Norethisterone

Ethinylestradiol British Pharmacopoeia (BP) Assay Standard

BP421

Ethinylestradiol

Etonogestrel ≥98% (HPLC)

Sigma-Aldrich

SML0356

Etonogestrel

Ethinyl Estradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1480

Ethinyl Estradiol

17α-Ethynylestradiol ≥98%

Sigma-Aldrich

E4876

17α-Ethynylestradiol

Anita Nelson et al.
Obstetrics and gynecology, 122(6), 1205-1213 (2013-11-19)
To evaluate the efficacy and safety of two low-dose levonorgestrel intrauterine contraceptive systems. Nulliparous and parous women aged 18-35 years with regular menstrual cycles (21-35 days) requesting contraception were randomized to 3 years of treatment with one of two levonorgestrel
Abbey B Berenson et al.
Obstetrics and gynecology, 121(5), 951-958 (2013-05-03)
Many U.S. health care providers remain reluctant to prescribe intrauterine devices (IUDs) to teenagers as a result of concerns about serious complications. This study examined whether 15-19-year-old IUD users were more likely to experience complications, failure, or early discontinuation than
Jantien Visser et al.
The Cochrane database of systematic reviews, 3(3), CD003990-CD003990 (2013-04-02)
Adequate contraceptive advice is important in both women with diabetes mellitus type 1 and type 2 to reduce the risk of maternal and infant morbidity and mortality in unplanned pregnancies. A wide variety of contraceptives are available for these women.
Ioannis D Gallos et al.
Obstetrics and gynecology, 121(6), 1165-1171 (2013-07-03)
To identify predictors and to estimate their prognostic accuracy for regression and relapse of endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system or oral progestogens. This was a cohort study of women treated with levonorgestrel-releasing intrauterine system or oral progestogens for
Virpi Koskela-Niska et al.
International journal of cancer, 133(7), 1680-1688 (2013-03-26)
Postmenopausal hormone therapy (HT) associates with an increased risk of ovarian cancer, but its' influence on tumor histology is not as well known. Therefore, we evaluated the effect of various types of HT on the risk of epithelial ovarian cancer
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.